Ventricular Tachycardia vs. Ventricular Fibrillation: A Clinical Primer for Cardiology Teams

Not all dangerous heart rhythms are the same – and the differences between them carry real clinical weight. Ventricular tachycardia and ventricular fibrillation are both potentially lethal arrhythmias, both rooted in the ventricles, and both capable of causing sudden cardiac arrest. But their mechanisms, presentations, and management differ in ways that shape everything from immediate treatment decisions to long-term device programming. This primer provides a clear, practical grounding in both rhythms for the full cardiology care team.

The Normal Electrical Sequence – and How It Breaks Down

In a healthy heart, every beat begins in the sinoatrial (SA) node, travels through the atrioventricular (AV) node, and spreads simultaneously through the His-Purkinje system to activate both ventricles in a coordinated, synchronized contraction. This elegant sequence – lasting a fraction of a second – produces the QRS complex on the electrocardiogram and, more importantly, produces a heartbeat that effectively pumps blood.

Ventricular arrhythmias arise when this sequence is disrupted by abnormal electrical activity originating in the ventricular myocardium itself, bypassing or overriding the normal conduction pathway. The degree of disruption – from a partial breakdown of organized conduction to a complete electrical chaos – determines whether the resulting rhythm is ventricular tachycardia or ventricular fibrillation, and determines the hemodynamic consequences.

Ventricular Tachycardia: Organized but Dangerous

Ventricular tachycardia (VT) is defined as three or more consecutive beats originating from a ventricular focus at a rate typically exceeding 100 beats per minute – though rates above 120–150 bpm are more clinically significant. The key feature that distinguishes VT from VF is that VT retains a degree of electrical organization: the ventricles are firing in a rapid but still-structured pattern, producing wide, aberrant QRS complexes on ECG.

VT exists on a spectrum of clinical severity:

• Non-sustained VT (NSVT):  Three or more ventricular beats lasting less than 30 seconds and self-terminating. NSVT may or may not cause symptoms (palpitations, brief lightheadedness) and is clinically significant primarily as a marker of underlying arrhythmic substrate and a potential precursor to sustained VT or VF.
• Sustained VT:  Lasting 30 seconds or longer, or requiring termination due to hemodynamic compromise. Sustained VT may be monomorphic (consistent QRS morphology, suggesting a fixed reentrant circuit) or polymorphic (varying QRS morphology, suggesting multiple foci or functional reentry). Hemodynamic stability varies widely – some patients tolerate sustained VT for minutes; others deteriorate immediately.
• VT storm:  Three or more distinct VT episodes within 24 hours, representing an urgent and potentially life-threatening escalation that requires immediate evaluation and management.

Because VT can maintain some degree of cardiac output – particularly at slower rates – patients are not always unconscious during VT. This is what makes VT diagnostically distinct from VF and, in some settings, makes catheter ablation and antiarrhythmic medication viable management options rather than immediate defibrillation.

Ventricular Fibrillation: Electrical Chaos and Immediate Collapse

Ventricular fibrillation (VF) is the complete breakdown of organized ventricular electrical activity into a chaotic, asynchronous state. There is no coordinated contraction, no effective pump function, and no cardiac output. The ECG shows irregular, rapid, disorganized waveforms without discernible QRS complexes. A person experiencing VF loses consciousness within seconds and enters cardiac arrest.

Without immediate defibrillation, VF is universally fatal. There is no spontaneous conversion, no pharmacologic option that consistently terminates VF fast enough to be the primary treatment, and no hemodynamic compensation possible when the ventricle is in electrical chaos. The 7–10% decline in survival with each passing minute without defibrillation reflects this ruthless physiology.

VF is most commonly triggered in the setting of acute ischemia (particularly STEMI), but it also occurs as a primary electrical event in patients with cardiomyopathy, channelopathies, electrolyte abnormalities, and reperfusion injury. It can also be initiated by VT that degenerates – a particularly important pathway in patients with structural heart disease.

In ventricular fibrillation, defibrillation is the only effective treatment. CPR sustains the patient, but it cannot restore a normal rhythm. Only the electrical shock of a defibrillator can. This is the physiology that makes wearable defibrillators – and the compliance to keep them on – a matter of life and death.

Comparing the Two Rhythms at a Glance

Feature	Ventricular Tachycardia (VT)	Ventricular Fibrillation (VF)
Electrical organization	Present – rapid but structured QRS	Absent – chaotic, no organized QRS
Cardiac output	Reduced but may be partial	Zero – no effective pump function
Consciousness	May be preserved (esp. slower VT)	Lost within seconds
ECG appearance	Wide, rapid, regular or irregular QRS	Disorganized waveforms, no QRS
Primary treatment	Synchronized cardioversion if unstable; antiarrhythmics if stable	Immediate unsynchronized defibrillation + CPR
WCD response	Detects and treats sustained VT meeting programmed criteria	Detects immediately; delivers defibrillation shock
Can degenerate to VF?	Yes – especially polymorphic VT and fast monomorphic VT	N/A – VF is the endpoint

How WCDs Detect and Distinguish the Two Rhythms

Accurate arrhythmia detection is the foundation of WCD performance. A wearable defibrillator that delivers unnecessary shocks – triggered by motion artifact, noise, or a non-dangerous rhythm – creates the shock anxiety and device removal that destroys compliance. A device that fails to deliver therapy when VT or VF is present fails its fundamental purpose. The sophistication of the detection algorithm is therefore one of the most clinically meaningful differentiators between WCD systems.

Modern WCDs use multi-channel ECG monitoring to distinguish pathological ventricular rhythms from normal or supra-normal variants, from supraventricular tachycardias, and from motion artifact. The key technical elements include:

• Rate criteria:  The detection algorithm evaluates whether the ventricular rate exceeds programmed thresholds for VT or VF detection, typically with separate zone-based programming for slower VT (monitoring only) and faster VT/VF (therapy delivery).
• Morphology analysis:  Advanced systems compare detected QRS morphology to the patient’s established baseline, helping distinguish wide-complex tachycardias of ventricular origin from conducted supraventricular rhythms.
• Multi-channel redundancy:  Using four ECG channels simultaneously means the system can cross-validate signals across multiple electrode pairs, requiring only one clean channel for analysis while maintaining detection sensitivity.
• Adaptive baseline learning:  Algorithms that continuously update to the patient’s current cardiac baseline reduce false detection from baseline QRS morphology changes, electrolyte shifts, or medication effects over the wearing period.

The Clinical Significance of False Positives – and How to Eliminate Them

False positive shock alarms – where the detection algorithm identifies a non-dangerous situation as requiring therapy – are among the most damaging clinical events in WCD management. A single false alarm can trigger shock anxiety that leads to device removal. Published literature has documented false positive rates in legacy WCD systems that significantly impact patient quality of life and compliance.

The relationship between false alarm rates and compliance is not linear – it is dramatically amplified by the psychological impact of the shock experience itself. A patient who removes their WCD because it is uncomfortable can be encouraged back into consistent wearing. A patient who removes their WCD because they are afraid of another unexpected shock alarm requires a fundamentally different intervention, with a much lower probability of achieving clinically sufficient wear time.

This is why 0% false positive shock alarm rate – the result achieved in the ACE-PAS study of 5,929 ASSURE patients – is not simply a performance statistic. It is a compliance driver, a quality-of-life determinant, and ultimately a survival factor.

How CareStation Reports Present VT and VF Episode Data

For physicians managing WCD patients through the arrhythmic risk window, remote access to episode data is as important as the device’s therapeutic capability. When a patient’s WCD detects a ventricular event – whether it delivers therapy or simply stores the episode – the treating physician needs rapid access to the ECG data, the rhythm characterization, and the patient’s subsequent clinical status.

Modern WCD platforms transmit episode data automatically, allowing the clinician to review the detected rhythm, assess whether the detection was appropriate, evaluate the clinical context (time of day, activity level, prior symptoms), and make management decisions without waiting for the patient to return to the clinic. A significant or recurrent arrhythmia detected on remote monitoring becomes an actionable clinical event – not a historical data point discovered three months later at a scheduled follow-up.

The ASSURE® Cardiac Recovery System: Built for This Moment

The ASSURE® Monitor at the heart of the Kestra Cardiac Recovery System uses two proprietary detection technologies – Quad Channel Processing™ and Adaptive Patient Intelligence™ – that together address both the technical and human challenges of accurate arrhythmia detection in ambulatory patients.

Quad Channel Processing uses four independent ECG channels simultaneously. Because only one noise-free channel is required for rhythm analysis, the redundancy provides exceptional signal reliability across different body positions, activity levels, and physiologic states – eliminating one of the primary sources of false positive detections in single-channel systems.

Adaptive Patient Intelligence continuously learns each individual patient’s cardiac baseline – accommodating the normal QRS morphology variations that occur with heart rate changes, postural shifts, and evolving clinical status – filtering out artifact and non-pathological rhythm changes that would trigger false alarms in fixed-parameter detection systems.

The result, validated in 5,929 real-world patients in the ACE-PAS study, is a 0% false positive shock alarm rate. Ninety-four percent of ASSURE patients never experienced a false alarm of any kind. When a real VT or VF event occurred, the first-shock success rate exceeded 95%. This is the detection performance that cardiologists and their patients deserve – precision that protects without unnecessary alarm, and power that responds when it genuinely matters.

© Kestra Medical Technologies, Ltd.  ·  kestramedical.com  ·  For informational purposes. Not a substitute for professional medical advice.